Evidence map›Paper›PMID 30174399›Full record

ArticleAnnals of gastroenterology

Everolimus with or without mycophenolate mofetil in a liver transplantation setting: a single-center experience.

Εvangelos Cholongitas, Ioannis Goulis, Eleni Theocharidou, Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Olga Giouleme, Aliki Angelaki, Themistoklis Vasiliadis, Vasilios Papanikolaou and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Εvangelos Cholongitas4 Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongitas, Ioannis Goulis, Aliki Angelaki, Evangelos Akriviadis), Greece.
Ioannis Goulis4 Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongitas, Ioannis Goulis, Aliki Angelaki, Evangelos Akriviadis), Greece.
Eleni Theocharidou2 Propedeutic Department of Internal Medicine, Medical School of Aristotle University, Hippokration Hospital, Thessaloniki (Eleni Theocharidou, Olga Giouleme), Greece.
Nikolaos AntoniadisDepartment of Transplant Surgery, Aristotle University of Thessaloniki (Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou), Greece.
Ioannis FouzasDepartment of Transplant Surgery, Aristotle University of Thessaloniki (Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou), Greece.
George ImvriosDepartment of Transplant Surgery, Aristotle University of Thessaloniki (Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou), Greece.
Olga Giouleme2 Propedeutic Department of Internal Medicine, Medical School of Aristotle University, Hippokration Hospital, Thessaloniki (Eleni Theocharidou, Olga Giouleme), Greece.
Aliki Angelaki4 Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongitas, Ioannis Goulis, Aliki Angelaki, Evangelos Akriviadis), Greece.
Themistoklis Vasiliadis3 Department of Internal Medicine, Papageorgiou General Hospital, Aristotle University of Thessaloniki (Themistoklis Vasiliadis), Greece.
Vasilios PapanikolaouDepartment of Transplant Surgery, Aristotle University of Thessaloniki (Nikolaos Antoniadis, Ioannis Fouzas, George Imvrios, Vasilios Papanikolaou), Greece.
Evangelos Akriviadis4 Department of Internal Medicine, Medical School of Aristotle University, Hippokration General Hospital of Thessaloniki (Evangelos Cholongitas, Ioannis Goulis, Aliki Angelaki, Evangelos Akriviadis), Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study evaluated the efficacy, safety, and impact on renal function of everolimus in patients after liver transplantation (LT) with or without mycophenolate mofetil (MMF).

methodsWe evaluated LT recipients with calcineurin inhibitor (CNI)-related renal dysfunction after everolimus initiation. Laboratory data, including evaluation of renal function based on glomerular filtration rate (GFR) at baseline (i.e., everolimus initiation) and at the end of follow up, were analyzed.

resultsFifty consecutive patients started taking everolimus at 30 months post-LT (range: 1-240), 6 as monotherapy and 44 in combination with MMF. After 30.5 months (range: 6-112), all patients were alive, without any biochemical evidence of a rejection episode or recurrence of hepatocellular carcinoma. The mean GFR, based on the Modification of Diet in Renal Disease equation, was 53±13 mL/min at baseline and 59±12 mL/min at the end of follow up (P=0.031). Eleven (22%) of the patients had GFR <60 mL/min at baseline but returned to GFR >60 mL/min by the end of follow up. In multivariate analysis, the time between the development of renal dysfunction and everolimus initiation was the only factor independently associated with GFR improvement (odds ratio [OR] 0.85, 95% confidence interval [95%CI] 0.76-0.96; P=0.007). Everolimus was stopped in 11 patients (22%) at the end of follow up because of adverse events.

conclusionA CNI-free everolimus-based regimen was effective in LT recipients with renal dysfunction and was associated with an improvement in GFR.

Indexed as

Everolimushepatocellular carcinomaliver transplantationmammalian target of rapamycin inhibitorrenal function

Identifiers

PMID30174399
PMCPMC6102469

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.